"We are planning to initiate a large phase 3 multicentre study to
evaluate the efficacy and safety of the vaccine," Bharat Biotech said
in a letter to the principal secretaries of these states. The
Hyderabad-based company intends to recruit about 20,000 participants
across India, with about 2,000 people in each state, for the trials.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotech-to-start-phase-iii-trials-for-covaxin/articleshow/78303337.cms
No comments:
Post a Comment